We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Lateral Flow Test Detects Bacteria Causing Gingivitis and Cardiovascular Diseases

By LabMedica International staff writers
Posted on 20 Oct 2023

Gingivitis, the initial stage of gum disease, is caused by bacteria that can make their way into the bloodstream and result in cardiovascular disease as well as other serious health conditions. More...

A newly designed device now provides an early warning system for tooth decay that may result from conditions like gingivitis and periodontitis.

In order to develop the gingivitis test, engineers at the University of Cincinnati (Cincinnati, OH, USA) faced the challenge of creating a device capable of identifying the specific bacteria responsible for gingivitis. The researchers, who have been exploring biosensing for various applications, are focusing on saliva for point-of-care (POC) tests. Saliva is an ideal substance for testing since it's easy to collect and plentiful. However, saliva is also a complex mixture containing elements like proteins, peptides, DNA, and other compounds, each potentially signaling different health conditions, which makes isolating a particular biomarker for analysis difficult.

To resolve this issue, researchers pretreated the sample using potato starch to remove a protein called amylase that could interfere with the test results. Their point-of-care lateral flow assay (LFA) device uses antibodies that react to the endotoxins found in the bacteria. The team will undertake further development to improve assay sensitivity using saliva samples and explore its ability to detect multiple lipopolysaccharides (LPS) molecules related to diseases for more accurate diagnostics of patients' health. Finally, because the sensitivity of the current antibody-based detection is significantly affected by the performance of the conjugate antibody, the researchers will work on developing aptamer-based sandwich lateral flow assay for improved flexibility and performance.

“It’s been quite the challenge to get to the point where we can detect this toxin created by the bacteria responsible for gingivitis,” said Andrew Steckl, an Ohio Eminent Scholar and distinguished research professor in UC’s College of Engineering and Applied Science. “There are good reasons to use saliva. It’s relatively plentiful and easy to obtain through noninvasive methods. And saliva has a lot of important elements that can act as indicators of your health.”

Related Links:
University of Cincinnati 


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.